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Background: Thresholds for statistical significance when assessing meta-analysis results are being insufficiently
demonstrated by traditional 95% confidence intervals and P-values. Assessment of intervention effects in systematic
reviews with meta-analysis deserves greater rigour.
Methods: Methodologies for assessing statistical and clinical significance of intervention effects in systematic
reviews were considered. Balancing simplicity and comprehensiveness, an operational procedure was developed,
based mainly on The Cochrane Collaboration methodology and the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) guidelines.
Results: We propose an eight-step procedure for better validation of meta-analytic results in systematic reviews (1)
Obtain the 95% confidence intervals and the P-values from both fixed-effect and random-effects meta-analyses and report
the most conservative results as the main results. (2) Explore the reasons behind substantial statistical heterogeneity using
subgroup and sensitivity analyses (see step 6). (3) To take account of problems with multiplicity adjust the thresholds for sig-
nificance according to the number of primary outcomes. (4) Calculate required information sizes (≈ the a priori required
number of participants for a meta-analysis to be conclusive) for all outcomes and analyse each outcome with trial sequen-
tial analysis. Report whether the trial sequential monitoring boundaries for benefit, harm, or futility are crossed. (5) Calculate
Bayes factors for all primary outcomes. (6) Use subgroup analyses and sensitivity analyses to assess the potential impact of
bias on the review results.
(7) Assess the risk of publication bias. (8) Assess the clinical significance of the statistically significant review results.
Conclusions: If followed, the proposed eight-step procedure will increase the validity of assessments of intervention effects
in systematic reviews of randomised clinical trials.Introduction
Systematic reviews summarise the results from rando-
mised clinical trials. Meta-analysis is the main statistical
method used in systematic reviews to analyse pooled re-
sults of trials [1,2]. Some claim that results of systematic
reviews should be considered hypothesis-generating and
should primarily serve the purpose of designing future
randomised clinical trials [3-5]. Others consider system-
atic reviews with meta-analysis the highest level of evi-
dence assessing the effects of healthcare interventions
[1,2]. Studies have clearly shown that results of meta-* Correspondence: jcj@ctu.dk
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unless otherwise stated.analyses of trials with low risk of bias are more reliable
than results of single large trials [6-11]. Inthout and
colleagues quantified the error rates for evaluations
based on single conventionally powered trials (80% or
90% power) compared to evaluations based on random-
effects meta-analyses of a series of smaller trials [6].
When a treatment was assumed to have no effect but
heterogeneity was present, the error rates for a single
trial were increased more than 10-fold above the nom-
inal rate [6]. Conversely, for meta-analyses on a series of
trials, the error rates were correct [6]. When selective
publication was present, the error rates were always in-
creased, but they still tended to be lower for a series of
trials than in a single trial [6]. It also appears intuitively
evident that inclusion of all used data from all rando-
mised clinical trials ever conducted shall be treated as a
higher level of evidence compared to the data from onlyal Ltd. This is an Open Access article distributed under the terms of the Creative
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atic review with meta-analysis cannot be conducted with
the same scientific cogency as a randomised clinical trial
with pre-defined high-quality methodology addressing an a
priori and quantitatively hypothesised intervention effect.
Systematic review authors often know some of the eligible
randomised clinical trials before they prepare their protocol
for the systematic review, and hence, the review method-
ology is partly data driven. Nevertheless, understanding the
inherent methodological limitations of a systematic review
should lead to minimisation of these methodological limita-
tions and optimisation of the remaining review method-
ology, which is the objective of this paper.
We recently described an operational five-step procedure
for valid assessment of statistical and clinical significance in
a single randomised clinical trial [12]. We will now, in a
comparable manner, describe an eight-step procedure for a
more valid assessment of results of systematic reviews of
randomised clinical trials. Our procedure is based on and
designed to be an extension to The Cochrane Collaboration
Handbook and the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) principles
[13,16-19]. The eight-step procedure can be used as part of
a planned systematic review methodology or can be used to
assess the validity of results from already published system-
atic reviews [20].
The following eight sections of the manuscript will
correspond to each step of the proposed procedure.
Methods
Step 1: meta-analysis, the 95% confidence interval, and
the P-value
In a meta-analysis, a summary statistic is calculated for
each included trial, describing the observed intervention
effect [13]. Then, an aggregated intervention effect esti-
mate is calculated as a weighted average of the inter-
vention effects estimated from the individual trials [13].
Review authors should always report both the confidence
interval and the corresponding exact P-value from all
meta-analyses. The confidence interval will show the
range of uncertainty (considering the chosen threshold for
statistical significance) around the aggregated intervention
effect estimate. The P-value will show the probability of
obtaining the observed or even a larger difference in inter-
vention effect (disregarding possible bias) assuming that
the null hypothesis is true (the null hypothesis implies that
there is no difference in effect between the compared
interventions) [12].
In a fixed-effect meta-analysis, the underlying assump-
tion is that all of the included trials estimate the same
intervention effect, i.e., differences in observed effects
across trials are assumed to be caused by random error
(‘play of chance’) [13]. In a random-effects meta-analysis,
the underlying assumption is that the included trials donot estimate the same intervention effects – it is as-
sumed that the estimates of individual trial intervention
effects follow a normal or a log normal distribution [13].
The most commonly used random-effects model is the
DerSimonian and Laird model [21]. However, the Hartung-
Knapp-Sidik-Jonkman random-effects model assuming a
t-distribution of log (RR) (for dichotomous outcomes)
seems to be a more valid meta-analysis method [22]. It
is often likely that a given intervention will have different
effects across the included trials depending on different
forms of the interventions, different definitions of the out-
comes, different types of included participants, etc. The
random-effects model assumption will, therefore, often be
more realistic than the fixed-effect model assumption
[13]. If there is absence of statistical heterogeneity (the be-
tween trial variance of the estimated intervention effects is
close to zero [23]), then the fixed-effect and the random-
effects models will show identical results [13]. If there is
substantial statistical heterogeneity, the fixed-effect meta-
analysis will, in some circumstances, show erroneous
results because the between trial variance is not appropri-
ately accounted for. In such a case, the random-effects
meta-analysis result should be regarded as the main result.
On the other hand, if one or two trials accounts for
approximately 80% or more of the total weight in a
fixed-effect meta-analysis, then the random-effects meta-
analysis might show erroneous results because the larger
trials with the greatest precision are inappropriately
down-weighted [24]. In such a case, the fixed-effect meta-
analysis result should be regarded as the main result. We
recommend always reporting results from both fixed-
effect and random-effects meta-analyses. If the fixed-effect
and the random-effects meta-analyses show different re-
sults, then the most conservative result (the analysis with
the highest P-value) should be chosen as the main result
[13]. Choosing the most conservative result will take ac-
count of the mentioned pitfalls of the two analyses [13].
Substantial discrepancies between the results of the two
methods should be reported and discussed thoroughly
(see step 2).
Step 2: investigating statistical and clinical heterogeneity
Implications of clinical and statistical heterogeneity
should always be considered when meta-analyses are
conducted [13,25,26]. Substantial statistical heterogen-
eity may be identified by visual inspection of forest plots
and by the calculated statistical heterogeneity (for example,
I2 or D2) [13,25,26]. It must be noted that the statistical
heterogeneity (both I2 and D2) will increase by including
trials with large sample sizes because the variance of the
trials’ intervention effects will decrease with the increased
sample size and event size. As a result, the ratio of the be-
tween trial variance to the total variance will also increase.
In other words, small and clinically irrelevant intervention
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istical heterogeneity when confidence intervals of the trial
intervention effects are narrow [27]. Statistical heterogen-
eity should always be interpreted with caution but espe-
cially when analysing large sample sizes [21]. Underlying
reasons behind significant statistical heterogeneity in
meta-analyses should be investigated by assessing trial
characteristics in subgroup analyses and sensitivity ana-
lyses (see step 6), and it should be reconsidered if all of
the included trials should be included in the analyses. For
example, if the statistical heterogeneity seems to be caused
by different forms of the intervention or a different assess-
ment procedure, then the need for excluding some of the
trials from the main analysis should be considered. If any
trial is excluded from any analysis, then the reasons
for excluding the trial should be clearly reported in
the manuscript.
Post hoc analyses
Ideally all analyses in a systematic review should be
planned at the protocol stage, but post hoc analyses might
be warranted if unexpected clinical or statistical hetero-
geneity is identified during the analysis of the review re-
sults. Nevertheless, post hoc analyses should always be
interpreted with great caution and it should be made very
clear, which analyses were pre-defined in the published
protocol and which were not. Post hoc analysis should be
regarded as exploratory and hypotheses generating.
Step 3: problems with multiplicity due to multiple
outcomes
The overall risk of falsely rejecting the null hypothesis for
at least one outcome (the family-wise error rate) will in-
crease with the number of outcome comparisons [28,29].
Problems with multiplicity in systematic reviews have
major implications for the interpretation of the confidence
intervals and the P-values [29,30] – and problems with
multiplicity are often not accounted for in systematic re-
views [28,29,31]. For example, thresholds for significance
in meta-analyses are rarely adjusted if more than one
primary outcome is used [13].
Most systematic reviews will include multiple outcome
comparisons, and if review authors are free to choose
and highlight single results among the many compari-
sons, there will be an increased risk of false declaration
on the effectiveness of an assessed intervention. Data
driven post hoc analyses will be avoided if the review
methodology is clearly pre-defined and not changed dur-
ing the analysis of the review results. A straightforward
way to deal with some of the multiplicity problems is to
publish a protocol before the literature search begins
(for example, at PROSPERO (http://www.crd.york.ac.uk/
PROSPERO/)) [13,31-33]. In the protocol, the statistical
methodology should be described in detail, including aclear definition of the primary, secondary, and explora-
tory outcomes [13,31-33]. Proper adjustments according
to problems with multiplicity (see below) should be esti-
mated based on the outcome hierarchy specified in the
protocol. The main conclusions of the review ought to
be based on the results on the primary outcome/s.
Hence, adjustments due to problems with multiplicity
may also be limited to the primary outcome/s. This will
in itself limit the risk of type I error and will make the
threshold adjustments simpler and practically feasible. If
an outcome is assessed a multiple number of times, then
either the thresholds for significance should be adjusted
accordingly or the time point of primary interest should
be pre-specified.
A systematic review should summarise all available
evidence for a given medical intervention and choosing
only one primary outcome will often be too restrictive.
In advance, it will often be unknown, which outcomes
the eligible trials have used and it is important to assess
both beneficial and harmful intervention effects [5]. It is,
therefore, often advisable to use more than one patient-
relevant primary outcome in a systematic review. The
Cochrane Collaboration recommends using up to three
primary outcomes – for example, all-cause mortality,
serious adverse events, and quality of life [13]. The use
of more than one primary outcome (co-primary out-
comes) necessitates adjustments of the thresholds for
significance because of problems with multiplicity [34].
Different statistical methods have been proposed to
adjust confidence intervals and P-values when multiple
outcome comparisons are used [12]. Most adjustment
methods have focused on adjustments of the P-value
threshold, but adjusted confidence intervals can often be
calculated based on an adjusted P-value and an effect
estimate [12,35,36]. There is an extensive statistical litera-
ture about problems with multiplicity in observational
studies and randomised clinical trials [29], but problems
with multiplicity in systematic reviews have received lim-
ited attention [29,31]. Some methods have been developed
to deal with problems with multiplicity in systematic
reviews [37-39], but no simple and completely satisfactory
solution to the problem of multiple comparisons in sys-
tematic reviews has been developed yet [29,31].
The Bonferroni procedure divides the specified P-value
threshold (for example, 0.05) with the number of outcome
comparisons and this method can be used to control the
family-wise error rate [34]. If it is plausible that there is
no correlation between multiple primary outcomes,
then Bonferroni adjustment may be used. However, the
Bonferroni procedure is mostly a too conservative adjust-
ment method as most outcomes are interdependent (for
example, all cause mortality and serious adverse events
will often be positively correlated outcomes) [34]. To cal-
culate more precise adjustments of the thresholds for
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correlation between the co-primary outcomes will be
needed. Such a correlation will often be unknown and er-
roneous assumptions about correlations might lead to er-
roneous results. Because the ‘true’ multiplicity adjusted
thresholds for significance lie somewhere between the un-
adjusted threshold (for example, 0.05) and the Bonferroni
adjusted threshold, we suggest a pragmatic approach. We
suggest dividing the pre-specified P-value threshold
with the value halfway between 1 (no adjustment) and the
number of primary outcome comparisons (Bonferroni
adjustment). This will result in a multiplicity adjusted
threshold using 1 primary outcome = 0.05, 2 primary
outcomes = 0.033, and 3 primary outcomes = 0.025.
The use of full Bayesian statistics can account for prob-
lems of multiplicity due to multiple testing [24,40,41].
However, this use would imply integration of complicated
models and software for analysing the review results
[24,40,41] and would entail the need for specifying mul-
tiple prior distributions, which has its own problems
[12,24,40,41].
Step 4: trial sequential analysis
Required information size
If the sample size has not been reached in a randomised
clinical trial, then the threshold for statistical significance
ought to be adjusted [12,42]. A similar methodology should
apply to a meta-analysis that does not reach a required
information size (≈ the a priori required number of par-
ticipants for a meta-analysis to be conclusive) [25,26].
The 95% confidence interval may show the range of un-
certainty of the observed intervention effect estimate
and may improve the interpretability of meta-analysis
result. However, reporting results from meta-analyses
without linking the confidence intervals, the interven-
tion effect estimates, and the P-values to an estimated
required information size is erroneous for a number of
reasons:
 Most review authors do not assess if an accrued
information size is sufficient or not to detect or
reject a given intervention effect, and this is
problematic as nearly all meta-analyses in systematic
reviews are underpowered (the meta-analyses do not
have enough information to reject or accept the null
hypothesis when the null hypothesis is false)
[25,26,43]. Without an estimation of a required
information size it is difficult to interpret an
apparent neutral (no significant difference)
meta-analysis result – it becomes unclear whether a
neutral meta-analysis result indicates that there
is no difference in effect between the compared
interventions, or if the result indicates that the
information size is too small to demonstrate ordiscard the anticipated intervention effect [11].
Furthermore, meta-analyses with too small accrued
information size (sparse data) have an increased risk
of either overestimating or underestimating the
effect size and variance [25,26,44-46]. Therefore,
without a required information size it will also be
difficult to interpret a meta-analysis result indicating
a difference in effect, i.e., an observed difference in
effect might be caused by the random error due to
the low information size.
 There should be a low risk of turning a significant
(for example, a P-value below 0.05) meta-analysis
result into an insignificant result when future trials
are included – ‘unstable’ meta-analysis results should
be avoided for obvious reasons. It has been shown
that a statistically significant meta-analysis based on
too low information sizes, often at a later time
point, will change from statistically significant to
statistically non-significant [25,26,47].
 The Cochrane Collaboration recommends that all
systematic reviews are updated at least every second
year [13], and there might be a lower chance of a
review being updated if a meta-analysis shows
significant results. If systematic review authors are
allowed to assess statistical significance each time
the review is updated without adjusting the level of
statistical significance, premature declaration of
effects will ensue and the risk of falsely rejecting
the null hypothesis will increase (see also step 3
for a description of other problems with
multiplicity) [14,25,26].
It is, therefore, of importance to estimate a required
information size before conducting a meta-analysis. To
estimate a required information size, it is necessary:
 To estimate an anticipated intervention effect, i.e., to
define a hypothesis alternative to the null hypothesis
(for example, a mean difference, an odds ratio, or a
hazard ratio [13,48]). This hypothesised difference in
effect between the compared intervention groups
should be based on the most realistic intervention
effect as suggested by prior evidence (for example,
results from former randomised clinical trials, or
known effects from other similar interventions
[49-51]). As supplementary analyses, the point
estimate from the meta-analysis on the
outcome and the limit of the 95% confidence
interval closest to no effect can be used as
anticipated intervention effects.
 To estimate a variance of the anticipated difference
in intervention effect (for example, a standard
deviation for a continuous outcome or a proportion
of control participants with an event for a
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be based on results from empirical data, for
example, former systematic reviews, former
randomised clinical trials, or large observational
studies.
 To estimate a variance of the intervention effect
estimates between trials (D2 = the percentage that
the between-trial variability constitutes of the sum
of the between-trial variability and a sampling error
estimate considering the required information size)
[25,26,52]. If a random-effects meta-analysis is
chosen as the one of primary interest, it may be
pre-defined that the observed between trial variance
(empirical variance) will be used to calculate the
required information size [47,52]. However, if the
observed heterogeneity is zero, it may not be unwise
to use a heterogeneity of 25% [47]. If a fixed-effect
meta-analysis is chosen as the one of primary
interest, then the variance between trials should be
zero (see step 1).
 To decide on an acceptable risk of falsely rejecting
the null hypothesis (alpha or type I error). As we
have described in step 3, to adjust the risk of
type I error according to the number of outcome
comparisons we suggest dividing a pre-specified
P-value threshold with the value halfway between 1
and the number of primary outcome comparisons.
 To decide on an acceptable risk of falsely confirming
the null hypothesis (beta or type II error). We
recommend 10% or 20%.
Required information sizes can easily be calculated
using the program trial sequential analysis which to-
gether with a user manual can be downloaded for free at
our website (http://www.ctu.dk/tsa/) [47]. The diversity-
adjusted required information size should be reported
for all primary and secondary outcomes in the protocol.
Review authors might be tempted to calculate the diver-
sity-adjusted required information size based on unrea-
listically large anticipated intervention effects – large
anticipated intervention effects lead to small required
information sizes and the thresholds for significance will
be less strict after the information size has been reached
[25,26]. This problematic incentive for using too large
anticipated intervention effects to reduce the required in-
formation size might be counterbalanced by the use of a
simple Bayes factor (see step 5).
Methods to adjust thresholds for significance if the
required information size has not been reached
Trial sequential analysis [25,26] or another valid sequen-
tial method [53] may be used to show if information size
adjusted thresholds for significance are crossed or not.
Trial sequential analysis uses the Lan-DeMets trialsequential monitoring boundaries based on a O’Brien-
Fleming alfa-spending function because the sample sizes
of the included trials vary. The monitoring boundaries for
benefit, harm, or futility show the adjusted thresholds for
significance (adjusted thresholds of the confidence inter-
vals and the P-values) if a required information size has
not been reached [25,26,47,54]. We recommend analysing
all primary and secondary outcome comparisons with trial
sequential analysis [25,26,47,54] or another valid sequen-
tial method [25,26,53].
Fixed-effect and random-effects trial sequential analysis
The trial sequential analyses should be performed using
both a fixed-effect and a random-effects model [14,25,26].
Analogous to the meta-analysis (see step 1), the trial
sequential analysis with the highest P-value should be
chosen as the primary. If a fixed-effect trial sequential ana-
lysis is of primary interest, then the variance between trials
should be zero because the underlying assumption behind
the fixed-effect model is that all included trials are
estimating the same intervention effect. This also
means that the calculation of the required information
size should not be adjusted according to variance between
trials if a fixed-effect meta-analysis is chosen as the one of
primary interest.
If the diversity-adjusted required information size is
reached or surpassed
If the diversity-adjusted required information size is
reached, then the traditional thresholds for significance
(95% confidence intervals not containing 1.00 for binary
outcomes or 0.00 for continuous outcomes, and a corre-
sponding P-value under 0.05) may be used unless these
thresholds are adjusted according to problems with multi-
plicity (see step 3).
Step 5: Bayes factor
A low P-value indicates that an observed result is un-
likely given the null hypothesis is true [12] – the P-value
relates to the probability that there is no difference in
effect between the compared interventions. Even a low
P-value from a meta-analysis can be misleading if there
is also a low probability that data are compatible with
the anticipated intervention effect (see step 4). In other
words, the probability that the actual measured differ-
ence in effect of the compared interventions resulted
from an a priori anticipated ‘true’ difference needs to be
considered. For this purpose it is helpful to calculate Bayes
factors for the primary outcome/s (http://www.ctu.dk/
tools-and-links/bayes-factor-calculation.aspx) [55,56].
Bayes factor is the ratio between the probability of the
meta-analysis result given the null hypothesis (H0) is true
divided by the probability of the meta-analysis result given








Observed effect size  
(null hypothesis is marked in red and the alternative 
hypothesis is marked in green)
0 0.25 0.50 0.75 1 1.25 1.5
Figure 1 A figure showing how Bayes factor will change
according to different observed effects. The red left vertical line
represents the null hypothesis (an effect of null), and the right green
vertical line represents an alternative hypothesis to the null hypothesis
with an effect of 1.0. The black curve shows that Bayes factor will be
1.0 when the observed effect size is exactly half of the effect size of the
alternative hypothesis; and the curve shows that Bayes factor will
decrease with increasing observed effect sizes.
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pothesis (HA) as the anticipated intervention effect
used in the calculation of the required information size
in the trial sequential analysis (see step 4) [12], but Bayes
factor can be defined differently [12]. Bayes factor as de-
fined here may be calculated via the following formula
(http://www.ctu.dk/tools-and-links/bayes-factor-calcula-
tion.aspx):







μA = the intervention effect hypothesised in the esti-
mation of the required information size (for example, a
mean difference, a log odds ratio, a log relative risk, or a
log hazard ratio).
δ^ = the intervention effect shown by the meta-analysis
result (for example, a mean difference, a log odds ratio,
a log relative risk, or a log hazard ratio). SE δ^ = standard
error of δ^ . Details about Bayes factor and relevant basic
statistical methodology may be found elsewhere [12,50].
A narrow confidence interval associated with a low
P-value does not, as mentioned, necessarily correspond to
a low Bayes factor – and a P-value less than 0.05 may
therefore, in some circumstances, misleadingly indicate
evidence for an intervention effect [50,55]. A P-value less
than 0.05 combined with a Bayes factor greater than 1.0
obtained from the observed data render more credit to
the null hypothesis being true than the alternative hypoth-
esis being true. A high Bayes factor will indicate that a
meta-analysis result should be interpreted with caution,
or, at least, indicate that the meta-analysis result is pro-
duced by an intervention effect that is lower than the an-
ticipated intervention effect. A low Bayes factor together
with a low P-value will correspond to a high probability of
an intervention effect similar to or greater than the anti-
cipated intervention effect used in the calculation of the
required information size (Figure 1).
The Bayes factor threshold for significance
A Bayes factor less than 0.1 (a tenfold higher likelihood
of compatibility with the alternative hypothesis than
with the null hypothesis) may be chosen as threshold for
significance [50]. However, spurious intervention effects
caused by sparse data (see step 4) will also affect Bayes
factor. Hence, if the required information size has not
been reached, then even a Bayes factor less than 0.1
should be interpreted with caution [12,57].
As mentioned in step 4, to reduce the required infor-
mation size there is a risk of review authors using
unrealistically large anticipated intervention effects in
the calculation of the required information size. This
problematic incentive will be counterbalanced by the use
of Bayes factor because Bayes factor will increase if themeta-analysis shows an intervention effect smaller than
the anticipated intervention effect (Figure 1). In other
words, if unrealistically large intervention effects are
anticipated, then observed unbiased data will often show
smaller and more realistic intervention effects which
will result in a relative high Bayes factor. The use of
Bayes factor might be an incentive for a more realistic and
smaller estimation of anticipated intervention effects,
which will generally increase the validity of meta-analysis
results and decrease the risk of meta-analysis, either
overestimating or underestimating intervention effects.
However, Bayes factor will still be misleading when an
unrealistically large anticipated intervention effect is
confirmed by ‘play of chance’, by an unrealistically large
observed intervention effect [12,50].
Step 6: the potential impact of systematic errors (‘bias’)
on the meta-analysis results
Overall risk of bias
We have in step 3 to 5 described how to assess and take
account of the risk of random error. However, it is of
utmost importance also to assess the risk of systematic
error (‘bias’) through subgroup analyses and sensitivity
analyses [13]. Empirical evidence has repeatedly shown
that trials with high risk of bias tend to overestimate bene-
fits and underestimate harms [58-64]. The bias risk do-
mains generation of allocation sequence, allocation
concealment, blinding of participants and treatment
providers, blinding of outcome assessors, incomplete
outcome data (see paragraph below), selective outcome
reporting, and industry funding have been shown to be of
particular importance [13,58-64]. A randomised clinical
trial should, therefore, only be classified as overall ‘low risk
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assessed as ‘low risk of bias’ [13,58-64]. The main conclu-
sion of the systematic review ought to based on results of
trials with low risk of bias – so, such an analysis should
always be presented. A subgroup analysis should always
be performed comparing the effects of trials with ‘low risk
of bias’ to trials with ‘high risk of bias’.The range of uncertainty due to the missing outcome data
If trial investigators have not used valid methods (for
example, multiple imputation) to deal with missing data
in the included randomised clinical trials [13], then there
is a risk of biased review results [20,65]. For example, if
a certain group of participants are systematically lost to
follow-up in only one of the compared intervention
groups, then the review results might show a difference
in effect between the compared groups due to attrition
bias. If individual patient data are available, then mul-
tiple imputation might be used by the review authors,
but even multiple imputation might lead to biased results
if data are ‘missing not at random’ [65,66].
For all meta-analyses, we recommend using at least
two sensitivity analyses to assess the potential impact of
the missing outcome data (risk of attrition bias) on the
meta-analysis results [67]. The first sensitivity analysis is
a ’best-worst-case’ scenario where it is assumed that all
participants lost to follow-up in the experimental group
have had a beneficial outcome (for example, had no ser-
ious adverse event); and all those with missing outcomes
in the control group have had a harmful outcome (for
example, have had a serious adverse event). The second
sensitivity analysis is a ’worst-best-case’ scenario where it
is assumed that all participants lost to follow-up in the
experimental group have had a harmful outcome; and
that all those lost to follow-up in the control group have
had a beneficial outcome. If continuous outcomes are
used, then a ‘beneficial outcome’ might be the group mean
plus 2 standard deviations (or 1 standard deviation) of the
group mean, and a ‘harmful outcome’ might be the group
mean minus 2 standard deviations (or 1 standard devi-
ation) of the group mean (see Additional file 1).
The results from both of these two extreme scenarios
will most likely be unrealistic. However, these sensitivity
analyses show the range of uncertainty due to missing
data. The primary meta-analysis result may then be re-
lated to the results from the sensitivity analyses. If the
primary meta-analysis result and the sensitivity analyses
show similar confidence intervals and P-values, then the
validity of the review results will increase considerably.
If the primary meta-analysis results differ substantially
from the results of the sensitivity analyses, then this
will show that there is a risk of biased results due to
attrition bias.Step 7: publication bias
Systematic reviews aim to identify and include all ran-
domised clinical trials addressing the question of the
review [13]. However, trials with certain results might
not be published for different reasons and this might
consequently bias the review results [13]. Funnel plots
can assess the risk of such ‘publication bias’ together with
other bias [13].
A funnel plot is a simple scatter plot with the inter-
vention effect estimates from the included trials (odds
ratios and risk ratios should be plotted on a logarithmic
scale) on the horizontal scale and the standard error of
the intervention effect estimate on the vertical scale [13].
For example, if smaller trials without statistically sig-
nificant effects remain unpublished, this will lead to an
asymmetrical appearance of the funnel plot with a gap
in the corner of the plot [13]. It is evident that such
publication bias may tend to overestimate intervention
effects [68].
Funnel plot should only be used to assess the risk of
bias if at least 10 trials are included in the meta-analysis
[13]. Funnel plots cannot be used to assess the risk of
publication bias if the included trials are of similar size
and some effect estimates are naturally correlated with
their standard errors and therefore can produce spurious
asymmetry in funnel plots [69]. Other types of bias or
‘true’ heterogeneity of the trial intervention effects might
also produce asymmetry [13]. Contour lines correspond-
ing to ‘milestones’ of statistical significance (for example,
P = 0.05) can be added to the funnel plot and may help
to differentiate between funnel plot asymmetry caused
by publication bias and other factors [70]. For example,
if trials appear to be missing in areas of statistical non-
significance, then this may indicate that the asymmetry
is due to publication bias. On the other hand, if the
supposed missing trials are in areas of higher statistical
significance, then the cause of the asymmetry may be due
to factors other than publication bias. If there are no trials
showing statistically significant effects, then publication
bias may not be a plausible explanation for funnel plot
asymmetry [13,71].
A number of tests can assess funnel plot asymmetry
(for example, Egger, Deeks, Harbourd, Begg) [13]. These
tests should be interpreted in the light of visual inspec-
tion of the funnel plot and the results from these tests
should be interpreted with caution. In general, the pro-
posed tests have relatively low power [13].
The ‘trim and fill’ method can be used to assess the ro-
bustness of the review results. The trim and fill method
aims to identify and correct funnel plot asymmetry arising
from publication bias [13,72]. The method removes the
smaller trials causing funnel plot asymmetry, use the
‘trimmed’ funnel plot to estimate the true ‘centre’ of the
funnel, and then includes both the removed trials and
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and fill method then provides an estimate of an interven-
tion effect estimate adjusted for the assumed publication
bias and the ‘missing’ trials are plotted. The trim and fill
method assumes that the funnel plot asymmetry is caused
by publication bias, but other factors (for example, hetero-
geneity) will often also cause or contribute to an asym-
metry [13]. Therefore, the results from the trim and fill
methods should be interpreted with caution and should
primarily be hypothesis generating.
We have in this paragraph summarised The Cochrane
Collaboration methodology to assess the risk of publication
bias. For a more detailed description of assessments of
publication bias, please consult The Cochrane Handbook
for Systematic Reviews of Interventions [13].
Step 8: statistical significance and clinical significance
It will be impossible to interpret any review result with-
out a thorough assessment of statistical significance and
step 1 to 7 has described how to assess statistical sig-
nificance. However, more than statistical significance is
required before an intervention is declared as being
effective, i.e., the size of the intervention effect must be
clinically relevant in addition to the statistical signifi-
cance. For clinically relevant outcomes, such as mortal-
ity, it is difficult to define a lower threshold for clinical
significance. Any prevention, whatever small, of patient-
important outcomes may seem relevant [11,12]. The
clinical implications of statistically significant results on
surrogate outcomes (‘indirectness’, in the GRADE system
[16]), for example, serum levels of cholesterol or viro-
logical response, can often be questioned even with
P-values far below 0.05 [11,12]. Regardless of the type
of outcome, small beneficial intervention effects will
often not have any clinical relevance if adverse effects
are taken into consideration [11,12]. Even rare serious
adverse effects may rule out the rational use of an other-
wise beneficial intervention [73]. To assess the clinical sig-
nificance of intervention effects it is important to perform
a thorough assessment of the balance between beneficial
and harmful effects [11,12]. It is also important to relate
the trial participants to a clinical population. Clinical im-
plications of review results cannot be extrapolated to pa-
tient groups other than the patients included in the review
[11]. Moreover, if a new intervention shows statistically
significant effects but the size of the intervention effect is
smaller compared to another intervention, then the new
intervention effect might be considered as not clinically
significant.
To avoid erroneous interpretations, assessment of the
clinical significance of an intervention effect should only
be assessed if statistical significance has been obtained,
i.e., that the prior seven steps of our procedure have
shown indications of a statistically significant result[74]. On the other hand, if statistical significance has
been reached, then clinical significance must be assessed
[11,12,16,73,74].
Preparing summary of findings tables according to the
GRADE guidelines is an excellent way to demonstrate
the clinical implications of review results [16-19] (Table 1).
Reporting confidence intervals, ‘minimal clinical relevant
differences’ for continuous outcomes, numbers-needed-
to-treat for binary outcomes, and median survival times
for survival data may also improve the clinical interpret-
ability of review results [2,11,12,16-19].
Recommendations
To assess the statistical and clinical significance of results
from systematic reviews, we propose the following eight-
step procedure:
1. Calculate and report the confidence intervals and
P-values from all fixed-effect and random-effects
meta-analyses. The most conservative result should
be the main result.
2. Explore the reasons behind substantial statistical
heterogeneity by performing subgroup analyses and
sensitivity analyses (see step 6).
3. Adjust the thresholds for significance (P-values and
the confidence intervals from the meta-analyses and
the risks of type I error in the trial sequential analysis)
according to the number of primary outcomes.
4. Calculate and report realistic diversity-adjusted
required information sizes and analyse all primary
and secondary outcomes in the review with trial
sequential analysis. Report if the trial sequential
monitoring boundaries for benefit, harm, or futility
are crossed [25,26]. The trial sequential analyses will
adjust the confidence intervals and the thresholds
for significance by relating the accrued data to the
required information sizes [25,26].
5. Calculate and report Bayes factor for the primary
outcome/s based on a pre-specified anticipated
intervention effect (same anticipated intervention
effect as the one used to estimate the required
information size) (http://www.ctu.dk/tools-and-
links/bayes-factor-calculation.aspx). A Bayes factor
less than 0.1 (a tenfold higher likelihood of com-
patibility with the alternative hypothesis than with
the null hypothesis) may be used as threshold for
significance.
6. Use subgroup analysis and sensitivity analyses to
assess the potential impact of systematic errors
(bias).
7. Assess the risk of publication bias (funnel plot).
8. Assess clinical significance of the review results if
the prior seven steps have shown statistically
significant results.
Table 1 Quality assessment criteria according to GRADE adopted after reference [16]
Study design Levels of confidence in estimate Decrease confidence estimate if Increase confidence estimate if
Randomised clinical trials High Risk of bias Large intervention effect
One level if serious One level if large
Two levels if very serious Two levels if very large
Moderate Imprecision Dose response
One level if serious One level if evidence of dose response
Two levels if very serious
Observational studies Low Indirectness All plausible confounding
One level if serious One level if confounding would reduce a
demonstrated effect
Two levels if very serious
Very low Heterogeneity All plausible confounding
One level if serious One level if confounding would suggest a
spurious effect when results show no effect
Two levels if very serious
Publication bias
One level if serious
Two levels if very serious
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assessment of intervention effects in systematic reviews
with meta-analytic methods, and we present an example
of how the eight-step assessment can be used to assess
statistical significance and clinical significance (see
Additional file 1). For simplicity, we have only assessed
the result of the primary outcome.
The eight-step procedure, The Cochrane Collaboration
methodology, and the GRADE system
The eight-step procedure is designed to specify and assess
the thresholds for significance in systematic reviews – the
overall systematic review methodology should always be
based on The Cochrane Handbook for Systematic Reviews
of Interventions [2,13]. The GRADE system provides a
valid assessment of the quality of evidence in systematic
reviews [2,16-19]. Most of the methodological elements ofTable 2 Suggestions for a more valid assessment of intervent
Step 1 Calculate and report the P-values and the 95% confidence in
random-effects meta-analyses. The most conservative result
Step 2 Explore the reasons behind substantial statistical heterogene
Step 3 Adjust the thresholds for significance (P-values and the conf
the risks of type I error in the trial sequential analysis) accord
Step 4 Calculate and report a realistic diversity-adjusted required in
trial sequential analysis. Report if the trial sequential monitor
Step 5 Calculate and report Bayes factor for the primary outcome/s
estimate the required information size (http://www.ctu.dk/to
less than 0.1 (a ten-fold higher likelihood of compatibility wi
may be chosen as threshold for significance.
Step 6 Use subgroup analysis and sensitivity analyses to assess the
Step 7 Assess the risk of publication bias.
Step 8 Assess clinical significance of the review results if the prior s
All of these aspects should be prospectively planned and published in the protocolthe eight-step procedure, for example, trial sequential ana-
lyses, have already been used in several systematic reviews
(for example, [75,76]) but are neither described in The
Cochrane Handbook for Systematic Reviews of Interven-
tions nor the GRADE system. The eight-step procedure
summarises the necessary methodology to assess the
thresholds for significance and adds to the Cochrane
methodology and the GRADE system: adjustments of the
thresholds for significance according to problems with
multiplicity and small information sizes, estimations of re-
quired information sizes, best-worst and worst-best case
scenarios to assess the potential impact of missing data,
and a calculation of Bayes factor. Table 1 summarises how
GRADE may be used to assess the quality of the evidence
[16], and we present an overview in Table 3 of how trial
sequential analysis (step 4) may be used as a supplement
for a more thorough assessment of ‘imprecision’ [77].ion effects in systematic reviews
tervals from all fixed-effect and
should be the main result.
ity by performing subgroup analyses and sensitivity analyses (see step 6).
idence intervals from the meta-analyses and
ing to the number of primary outcome comparisons.
formation size and analyse all of the outcomes with
ing boundaries for benefit, harm, or futility are crossed.
based on the anticipated intervention effect used to
ols-and-links/bayes-factor-calculation.aspx). A Bayes factor
th the alternative hypothesis than with the null hypothesis)
potential impact of systematic errors (‘bias’).
even steps have shown statistically significant results.
for the systematic review before the literature search begins.
Table 3 How trial sequential analysis can supplement the assessment of GRADE for ‘imprecision’ [77]
Trial sequential analysis Assessment of imprecision [77]
If none of the sequential boundaries for benefit, harm, or futility
are crossed and the anticipated intervention effect is realistic.
The evidence should be downgraded two levels of quality according to
imprecision (see Table 1).
If one of the boundaries for benefit, harm, or futility are crossed
and the anticipated intervention effect is realistic.
The evidence should not be downgraded according to imprecision
(see Table 1).
If the anticipated intervention effect is considered unrealistic. The trial sequential analysis should be repeated using the limit of the
confidence interval, closest to zero effect from the traditional meta-analysis
as the anticipated intervention effect. If the sequential boundaries are
crossed then the level of evidence should not be downgraded (see Table 1).
If the sequential boundaries are not crossed, the trial sequential analysis
should be repeated, this time, using the intervention effect estimate from
the meta-analysis as the anticipated intervention effect. If the sequential
boundaries are crossed, then the evidence should be downgraded one level
of quality; if the sequential boundaries are not crossed, then the evidence
should be downgraded two levels of quality (see Table 1).
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We argue that a systematic review should be the pre-
rogative and the incentive for conducting new trials and
introducing new interventions into clinical practice. The
systematic review ought be at the top of the hierarchy of
evidence [6,7,11]. Nevertheless, there is a high risk of
biased review results if reviews are not conducted with
high methodological rigour. In order to avoid premature
and erroneous conclusions, we have described the import-
ance of valid thresholds for statistical and clinical signifi-
cance in a systematic review, and we have also described a
systematic step-wise methodological approach which will
increase the methodological validity and quality of the
interpretation of review results.
Strengths and limitations
The proposed eight-step procedure has strengths and
limitations.
The eight-step procedure has the strength that it: (1)
summarises The Cochrane Collaboration methodology
related to the specification and assessment of the thresh-
olds for significance in systematic reviews; (2) systemat-
ically adjusts the thresholds for significance according to
the number of primary outcome comparisons and the
fraction of the required information size that has been
reached; (3) provides a likelihood ratio of the probability
that a meta-analysis result is compatible with the null
hypothesis divided by the probability that the result is
compatible with an anticipated intervention effect; (4)
limits the incentives for review authors both to
overestimate and underestimate the anticipated inter-
vention effect (see step 4 and step 5); (5) provides a
more thorough assessment of the review results with
a specific and elaborated evaluation of imprecision which
may be used for a more accurate GRADE rating [16,77];
and (6) forces investigators and consumers of system-
atically reviewed clinical research to judge clinical
significance.Our methodology has limitations.
First, our eight-step procedure is based on already
well-established methodologies, but we lack large com-
parative studies comparing the use of the procedure to
‘usual practice’. We will address this issue in forthcom-
ing articles.
Second, the pragmatic approach we recommend to be
used for multiplicity adjustment (dividing 0.05 with the
value halfway between 1 and the number of primary
outcome comparisons) is not based on evidence. Our
approach is based on the fact that the ‘true’ multiplicity
adjusted threshold for significance lies between the un-
adjusted threshold and the Bonferroni adjusted thresh-
old (see step 3). Nevertheless, most systematic reviewers
do not adjust the thresholds for significance at all,
which seems worse than both the conservative approach
(Bonferroni adjustment) and our suggested pragmatic ap-
proach. As we have described in step 3, to calculate more
precise adjustments of the thresholds for significance in
systematic reviews an estimation of the correlation between
the co-primary outcomes will be needed (see step 3). Such
a correlation will often be unknown and erroneous assump-
tions about correlations might lead to erroneous results.
Third, the required information size, the trial sequen-
tial analysis, and the size of Bayes factor will all be highly
dependent on the choice of the anticipated intervention
effect which often will be difficult to quantify in advance.
To reduce this limitation, it will often be warranted to
perform sensitivity analyses using different estimations
of the anticipated intervention effects. For example, as
supplementary trial sequential analyses, the point esti-
mate from the meta-analysis on the outcome and the
limit of the 95% confidence interval closest to no effect
can be used as the anticipated intervention effects; or an
additional Bayes factor may be calculated using a smaller
(‘sceptical’) anticipated intervention effect (for example,
a relative risk halfway between the intervention effect
anticipated in the calculation of the required information
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tion of the anticipated intervention effects is a major
limitation of our procedure as well as Bayesian analyses.
To make the estimation of the anticipated intervention
effects as optimal and as objective as possible, we recom-
mend, as one option, to base the estimation of the antici-
pated intervention effect on former randomised clinical
trials. If this is done, then the results from the trials used
to estimate the anticipated intervention effects will prob-
ably be used again in the full review analysis, i.e., the
estimation of the required information size take the form
of an adaptive estimation [51,78]. Hence, the risk of type I
error will increase [51,78]. Because of this risk of circular
reasoning, ideally, it is, necessary to adjust the required
information size by applying a penalty for the weight of
data from former systematic reviews (or trials) [51,78]. If
the anticipated intervention effect estimate is based
on, for example, an estimation of a ‘minimally clinic-
ally relevant’ intervention effect, then no adjustments
will be needed. We acknowledge the theoretical need for
such further adjustments, but then, the review analyses
will become very complicated because the analysis me-
thods would differ, depending on how the anticipated
intervention effects are defined. Furthermore, our rec-
ommendations are already considerably tightening the
thresholds for significance in systematic reviews, and
if thresholds are too tight, there is a risk of ‘throwing the
baby out with the bath water’.
The trial sequential analysis, the required information
size, and Bayes factor may be influenced by post-hoc
adjustments and erroneous quantifications of the alterna-
tive hypothesis, especially if they have not been declared
transparently in a protocol published before the systematic
review begins. If the anticipated intervention effects are
clearly defined in a published review protocol, and if pre-
defined sensitivity analyses assess the uncertainty of the
estimation of the anticipated intervention effects, then
many of the problems with using anticipated intervention
effect will be limited. The uncertainty of the estimation
of the anticipated intervention effect is a challenge
and a major limitation – but remains a necessary evil. A
required information size and adjusted thresholds for sig-
nificance cannot be calculated without estimations of an
anticipated intervention effect.
We are sure that our eight-step procedure will be met
with critical comments. Our recommendations will lead
to fewer interventions which seem to offer benefits, the
introduction of effective interventions in clinical practice
may be delayed, and patient populations may stay with-
out evidence-based interventions. We agree with such
risks, but all things considered we do argue that a con-
servative scenario is more ethically defensible compared
to the present-day practice of implementing interven-
tions based on weak evidence [9,25,44,45,52,79]. Weargue that the advantages of the procedure outweigh the
disadvantages. The health care researchers must deliver
solid proof of more benefit than harms before interven-
tions are introduced into clinical practice.
Conclusions
If the proposed eight-step procedure is followed, this
may increase the validity of assessments of intervention
effects in systematic reviews.
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